ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical

International Trade Commission prohibits BMC from importing or selling infringing masks in U.S.

News provided by

Dec 23, 2014, 06:24 ET

SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) today announced its victory in a significant patent infringement action against Chinese medical device manufacturer BMC Medical Co., Ltd.

The International Trade Commission (ITC) ruled today that BMC's masks listed below infringe ResMed's patents, and entered an order prohibiting BMC from importing, advertising, or selling these masks in the United States:

iVolve nasal mask
iVolve N2 nasal mask
Willow nasal pillows mask
iVolve full face mask

"Changing lives with every breath is the foundation of ResMed's business. That focus drives our patient-centric approach to research and development. It's why our products are the highest quality and the most comfortable, and it's why we vigorously protect our patent portfolio," said David Pendarvis, ResMed chief administrative officer and global general counsel. "We are pleased the court has validated ResMed's intellectual property rights protecting those valuable innovations for the benefit of patients."

In its ruling, the ITC also sustained a BMC challenge to the one patent that ResMed asserted in this case against the BMC humidifier. ResMed will appeal the ITC's order on that patent and is considering further actions. ResMed has a portfolio of more than 5000 patents, pending patent applications and protected designs on flow generators, humidifiers and masks relating to CPAP therapy.

About ResMed
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:
For News Media	For Investors
Alison Graves	Agnes Lee
Director, Global Corporate Communications	Senior Director, Investor Relations
O: 858-836-6789	O: 858-836-5971
[email protected]	[email protected]